Anti-TNFalpha polyclonal antibody - R&D Systems
Latest Information Update: 15 Aug 2002
At a glance
- Originator R&D Systems
- Class
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 22 Oct 1997 New profile
- 22 Oct 1997 Preclinical development for Transplant rejection in USA (Unknown route)